**16th Annual Digestive Health Symposium**

February 23, 2024

**Purpose**

This two-day format allows for the combining of three annual symposiums into one; thereby expanding our audience base, introducing attendees to all digestive health tertiary medical and surgical services offered at our Digestive Health Institute. Agenda to be uploaded

**Target Audience**

Specialties – Medicine, Gastroenterology

Professions – Physician, Non-Physician, Allied Health Professional, EMT, Medical Assistant, Medical Student, Nurse, Nurse Practitioner, Other, Pharmacist, Physical Therapist, Registered Dietitian, Resident Physician, Social Worker

**Activity Objectives**

1 This program will provide, thorough formal lectures, question-and-answer sessions and a hands-on workshop, updates on new approaches in the diagnosis and management of gastrointestinal, liver diseases and cancer for invasive and non-invasive methods. The methods include case-based discussion, lecture, panel, simulation, and skill-based training.

2 Learn to manage biologic therapy around the time of surgery

Improving knowledge about management of biologic therapy during surgery

3 Understand optimization of medical therapy for inflammatory bowel disease

Start to use lab testing to check drug levels.

4 Review new drug therapies for Crohn's disease

Develop better understanding of which therapies to use for Crohn's disease as we get more options

5 Discuss cancer risk in the IBD patient

Ability to discuss risk of cancer development in patients with IBD as well as more biologic and immunomodulator therapy

6 Discuss what’s new in management of biliary and pancreatic diseases

Understand the latest developments in management of biliary and pancreatic diseases

7 To define evidence based approaches towards the diagnosis and treatment of non-cardiac chest pain, belching and potential extra-esophageal symptoms of GERD

Evidence for and against GERD as a potential cause of chest pain, laryngopharyngeal symptoms and belching

Evidence for and against GERD therapies for the same symptoms.

8 Review current diagnostic and treatment paradigms for Barrett’s and esophageal cancer

Develop the ideal future paradigm for detecting and treating Barrett’s and esophageal cancer.

Current diagnostic and treatment paradigms for Barrett’s cancer

9 To determine whether endoscopic therapies (TIF, Stretta, Overstitch) provide equivalent outcomes compared with anti-reflux surgery

To determine the individual factors for choosing between endoscopic

Evidence for traditional surgery for GERD

Review of current literature regarding endoscopic therapies for GERD

10 Which polyps to worry about, how to recognize them and how they can/should be removed

Interval colorectal cancers could be reduced by over 85% by eliminating polyp miss rate and assuring complete polyp resection

11 Incorporate advances in disease monitoring and quality metrics that should be utilized in the management of IBD patients

Facilitate utilization of biologic drug monitoring to improve care of patients.

12 Describe the medical and surgical management of perianal Crohn’s disease and know how to provide resources for patients

Improved non-operative and operative management of perianal Crohn’s disease as well as more referrals for specialized

13 Explain positioning of IBD Biologic therapies for Crohn’s disease and Ulcerative Colitis. Understanding when to refer to Tertiary care for complex cases

Evidence based approach to choosing first, second and third line therapies.

14 Upon completion of this course, participants should be able to:

• Screen, diagnose, and manage viral hepatitis B

• Screen, diagnose, and manage viral hepatitis C

• Diagnose and manage non-alcoholic fatty liver disease

• Diagnose and Manage patients with hepatocellular carcinoma

By providing updated medical education, this CME program will improve the clinical knowledge and skills in managing those common chronic liver diseases.

15 Understand the risks, benefits and appropriate utilization of the contemporary medical, surgical and endoscopic therapies for GERD patients.

Evidence based approach to choosing between medical, endoscopic and surgical therapy for patients with GERD

16 Understanding the risk of progression of pancreatic cysts. Understanding an evidence based approach to choosing an imaging modality for pancreatic cyst surveillance

Understanding the appropriate approach for when to send pancreatic cysts for surgical resection

Evidence based approach to choosing an imaging modality for pancreatic cyst surveillance and an approach for when to send pancreatic cysts for surgical resection

17 Evidence base approach to understanding the pros and cons of novel weight loss and bariatric options.

**Accreditation Statement**

The University of California, Irvine School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Designation Statement**

The University of California, Irvine School of Medicine designates this Live Activity for a maximum of 15.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**California Assembly Bill 1195 and 241**

This activity is in compliance with California Assembly Bill 1195 and 241, which require CME activities with patient care components to include curriculum in the subjects of cultural and linguistic competency & implicit bias. It is the intent of AB 1195 and AB 241 to encourage physicians and surgeons, CME providers in the State of California, and the Accreditation Council for Continuing Medical Education to meet the cultural and linguistic concerns of a diverse patient population and reduce health disparities through appropriate professional development. Please see the CME website, <https://www.meded.uci.edu/CME/> for AB 1195 and AB 241 resources.











**MOC Statement(s)**

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 15.00 MOC point(s) in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.ABMS

**Faculty & Planner Disclosures**

University of California, Irvine School of Medicine Continuing Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ninh T Nguyen, MD | Faculty | Speakers Bureau-Olympus Corporation|Speakers Bureau-endogastric solutions|Speakers Bureau-covidien - 02/22/2024 |
| David K Imagawa, MD, MD, PhD, FACS | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Any division)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Dillon Pharmaceutical |Independent Contractor (included contracted research)-Eisai, Inc. (Relationship has ended)|Independent Contractor (included contracted research)-Beigene (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-BD|Independent Contractor (included contracted research)-Merck (Any division) - 01/10/2024 |
| Matthew Whealon, MD | Faculty | Nothing to disclose - 02/20/2024 |
| Brian R Smith, MD, FACS, FASMBS | Co-Director, Faculty | Nothing to disclose - 10/11/2023 |
| Shaun C Daly, MD, FACS | Faculty | Nothing to disclose - 02/08/2024 |
| Steven Mills, MD | Faculty | Nothing to disclose - 02/20/2024 |
| Marcelo W Hinojosa, MD | Faculty | Nothing to disclose - 02/22/2024 |
| William To, PA-C | Faculty | Nothing to disclose - 02/08/2024 |
| Yvonne Nguyen, BS | Activity Coordinator | Nothing to disclose - 10/10/2023 |
| Kenneth Chang, MD | Course Director, Faculty | Consulting Fee-Apollo (Relationship has ended)|Consulting Fee-Aqua Medical|Consulting Fee-Boston Scientific Corporation|Consulting Fee-Cook Medical, Inc.|Consulting Fee-CREO Medical|Consulting Fee-EndoGastric Solutions, Inc|Consulting Fee-ERBE|Consulting Fee-Medtronic (Any division)|Consulting Fee-Olympus Corporation|Consulting Fee-Ovesco (Relationship has ended)|Consulting Fee-Pentax Medical (Relationship has ended) - 02/22/2024 |
| Skandan Shanmugan, MD | Co-Director, Faculty | Nothing to disclose - 10/18/2023 |
| Nimisha K Parekh, MD | Co-Director, Faculty | Advisor-Fresenius Kabi (Relationship has ended) - 02/23/2024 |
| Sana Ahmed, PA-C | Other Planning Committee Member | Nothing to disclose - 10/10/2023 |
| Jemell Joven, RN | Nurse Planner | Nothing to disclose - 10/10/2023 |
| Kishore Gadde, MD | Faculty | Nothing to disclose - 01/12/2024 |
| Zeljka Jutric, MD | Faculty | Nothing to disclose - 02/22/2024 |
| Kevin Sallo | Activity Administrator | Nothing to disclose - 12/13/2023 |
| Robert H Lee, MD | Faculty | Nothing to disclose - 01/20/2024 |
| Calvin Q Pan, MD | Faculty | Grant or research support-Gilead Sciences, Inc. - 12/24/2023 |
| Nadine Abi-Jaoudeh, MD, Professor  | Faculty | Grant or research support-Philips Medical Systems Inc|Grant or research support-Teclison Limited Inc|Grant or research support-Guerbet SA, Varian Inc.|Grant or research support-Instylla HES Inc|Grant or research support-Sirtex Medical Ltd|Grant or research support-Angiodynamics Inc |Ownership-Bruin Biosciences Inc|Consulting Fee-Innova Vascular Inc|Consulting Fee-Medtronic (Any division)|Consulting Fee-Histosonics Inc.|Consulting Fee-Lynx group LLC|Consulting Fee-Angiodynamics Inc.|Consulting Fee-Instylla HES Inc.|Consulting Fee-SIRTEX Inc.|Consulting Fee-Boston Scientific Corporation|Consulting Fee-Genentech (Any division)|Consulting Fee-F. Hoffmann-La Roche Ltd|Consulting Fee-AstraZeneca (Any division) - 02/08/2024 |
| Jennifer Kolb, MD | Faculty | Nothing to disclose - 01/21/2024 |
| Liyun Yuan, MD, PhD, Assistant Professor of Clinical Medicine | Faculty | Grant or research support-Gilead Sciences, Inc.|Grant or research support-Zydus|Grant or research support-Madrigal|Grant or research support-Intercept (Relationship has ended) - 01/18/2024 |
| Jennifer Christie, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Takeda Pharmaceuticals (Any division) (Relationship has ended)|Advisor-Evoke|Advisor-Olympus Corporation - 02/04/2024 |
| Jennifer Phan, MD | Faculty | Speakers Bureau-Boston Scientific Corporation|Speakers Bureau-Olympus Corporation|Speakers Bureau-Cook Medical, Inc.|Speakers Bureau-Intuitive Surgical - 02/22/2024 |
| Sarah Koller, MD, Assistant Professor Surgery | Faculty | Nothing to disclose - 01/29/2024 |
| Jenny S Sauk, MD | Faculty | Speakers Bureau-AbbVie (Any division)|Speakers Bureau-Prometheus Laboratories, Inc.|Consulting Fee-CorEvitas|Advisor-Roivant (Relationship has ended) - 02/09/2024 |
| Andrew W. Yen, MD | Faculty | Nothing to disclose - 01/23/2024 |
| C Gregory Albers, MD | Faculty | Honoraria-Nestle (Any division)|Honoraria-AbbVie (Any division)|Honoraria-Phathom Pharmaceuticals - 02/08/2024 |
| Harry Nguyen, DO | Faculty | Nothing to disclose - 01/28/2024 |
| Mark Salem, MD | Faculty | Nothing to disclose - 02/18/2024 |
| Farshid Dayyani, MD, PhD | Faculty | Consulting Fee-AstraZeneca (Any division)|Speakers Bureau-Astellas (Any division)|Speakers Bureau-Ipsen Biopharmaceuticals, Inc.|Speakers Bureau-Takeda Pharmaceuticals (Any division) - 02/08/2024 |
| Timothy Morgan, MD | Faculty | Nothing to disclose - 02/08/2024 |
| Sandra Sunhee Park, MD | Faculty | Speakers Bureau-AbbVie (Any division)|Speakers Bureau-Lilly (Any division)|Paid consultant-Nestle (Any division) (Relationship has ended)|Paid consultant-Takeda Pharmaceuticals (Any division) - 02/11/2024 |
| Ke-Qin Hu, MD | Faculty | Speakers Bureau-Gilead Sciences, Inc. (Relationship has ended) - 02/19/2024 |
| Kiran Sachdev, MD | Faculty | Nothing to disclose - 02/20/2024 |
| Robert Fearn, MBChB | Faculty | Nothing to disclose - 02/22/2024 |

**Agenda**

**[INSERT AGENDA HERE MANUALLY]**

**Acknowledgement of Commercial Support**

The University of California, Irvine School of Medicine would like the thank the following companies for their support of this educational activity:

 Fuji Film (Financial)

 Boston Scientific (Financial and In-Kind)